Pulse Biosciences CCO Kevin Danahy resigns effective immediately

PULSE BIOSCIENCES, INC.

Kevin P. Danahy resigned as Chief Commercial Officer on February 27, 2026.
Resignation effective immediately, not due to any disagreement with the company.
Danahy was key to early commercialization efforts; company wishes him well.
No replacement named; CEO Paul LaViolette signed the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.